The COVID-19 pandemic has decimated portions of our economy and resulted in major financial challenges for virtually all hospitals and healthcare systems. Hiring freezes and even reductions-in-force have occurred almost everywhere. As the economy emerges from its depths and hospitals begin to build back up again, everything is under consideration. Yet there are no shortcuts to take in the protection of human research subjects. Some believe that any cost-cutting measure applied to an organization’s HRPP will put people at greater risk. During this panel discussion, this false dichotomy will be examined and put to rest. Research leaders from two organizations will discuss how they reconfigured their HRPP to save their organization’s resources by: 1) Focusing local IRB attention on high-risk research; 2) Relying on IRB partners for multicenter clinical trials, at no cost; and 3) Implementing the industry’s most-used, state-of-the-art eIRB system at ZERO out-of-pocket cost.
Assess the financial realities and sponsor expectations during and after the COVID-19 pandemic
Create a vision for your HRPP that addresses these financial realities
Formulate a plan to transform your HRPP without sacrificing high-level ethical protections